Agios to Present IDH Program Insights at Tumor Metabolism Keystone Symposia
Cambridge, Mass. – February 22, 2013 – Agios Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that Katharine Yen, Ph.D., director, biology, will present insights into the company’s lead isocitrate dehydrogenase (IDH) program at the Tumor Metabolism Keystone Symposia being held February 24-March 1, 2013 in Keystone, Colo.
“This symposia is comprised of leading experts in cancer cell metabolism, including the founders of Agios, who have pioneered key advances in the field,” said Scott Biller, Ph.D., chief scientific officer. “We are delighted to be a part of this forum. The audience, along with our fellow session speakers, creates an ideal environment to discuss progress in the overall field and share updates on our IDH program.”
The schedule for Agios’ presentations is as follows:
Date & Time: Thursday, February 28, 2013 at 3:00 p.m. (MST)
Session: Tumor Metabolism (X4) Workshop 2: Novel Therapeutic Approaches
Session Chair: Katharine Yen, Ph.D., director, biology
Date & Time: Thursday, February 28, 2013 at 5:00 p.m. (MST)
Session: Influence of Metabolism on Epigenetic Regulation
Title: Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes
Presenter: Katharine Yen, Ph.D., director, biology
Dr. Yen’s presentation focuses on mutations in the isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) genes, which are found in acute myeloid leukemia, brain cancer, and several other tumor types. Dr. Yen will discuss the progress of Agios’ IDH1 and IDH2 drug discovery programs and research into the role of IDH mutations in cancer.
In addition, Agios founders Craig B. Thompson, M.D., Memorial Sloan-Kettering Cancer Center; Tak W. Mak, Ph.D., Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital; and Lewis C. Cantley, Ph.D., Weill Cornell Medical College, will participate in various sessions during the symposia. Dr. Thompson will also serve as the keynote speaker for the meeting on Tumor Metabolism.
About Agios Pharmaceuticals, Inc.
Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.
